[go: up one dir, main page]

UY29352A1 - 5-fenilpirimidinas i sustituidas en terapeutica - Google Patents

5-fenilpirimidinas i sustituidas en terapeutica

Info

Publication number
UY29352A1
UY29352A1 UY29352A UY29352A UY29352A1 UY 29352 A1 UY29352 A1 UY 29352A1 UY 29352 A UY29352 A UY 29352A UY 29352 A UY29352 A UY 29352A UY 29352 A1 UY29352 A1 UY 29352A1
Authority
UY
Uruguay
Prior art keywords
therapeutics
substituted
replaced
phenyl pyrimidines
carry
Prior art date
Application number
UY29352A
Other languages
English (en)
Inventor
Dr Thomas Grote
Dr Bernd Muller
Joachim Rheinheimer
Dr Barbara Nave
Dr Frank Schieweck
Dr Anja Schwogler
Dr Thorsten Jabs
Dr Carsten Blettner
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of UY29352A1 publication Critical patent/UY29352A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a 5-fenilpirimidinas I sustituídas cuyos grupos sustituyentes X e Y son tales como se describen en la Memoria Descriptiva; y en donde el radical pirimidina puede llevar un radical diferente de hidrógeno en la posición 2 y en donde el anillo fenilo puede no estar sustituído o puede llevar de 1 a 5 radicales L que son diferentes de hidrógeno, y las sales farmacéuticamente aceptables de 5-fenilpirimidinas sustituídas para usar en terapéutica, en particular en terapéutica o tratamiento de enfermedades cancerosas.
UY29352A 2005-01-31 2006-01-31 5-fenilpirimidinas i sustituidas en terapeutica UY29352A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05001955 2005-01-31

Publications (1)

Publication Number Publication Date
UY29352A1 true UY29352A1 (es) 2006-08-31

Family

ID=34933530

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29352A UY29352A1 (es) 2005-01-31 2006-01-31 5-fenilpirimidinas i sustituidas en terapeutica

Country Status (19)

Country Link
US (1) US20080146593A1 (es)
EP (1) EP1845991A2 (es)
JP (1) JP2008528535A (es)
KR (1) KR20070104893A (es)
CN (1) CN101111250A (es)
AR (1) AR054220A1 (es)
AU (1) AU2006208621B2 (es)
BR (1) BRPI0607108A2 (es)
CA (1) CA2595958A1 (es)
EA (1) EA014098B1 (es)
IL (1) IL184375A0 (es)
MX (1) MX2007008397A (es)
NZ (1) NZ556448A (es)
PE (1) PE20061042A1 (es)
TW (1) TW200637556A (es)
UA (1) UA87895C2 (es)
UY (1) UY29352A1 (es)
WO (1) WO2006079556A2 (es)
ZA (1) ZA200707315B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066655A2 (en) * 2006-09-07 2009-06-10 Neurosearch A/S Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
TW200836741A (en) * 2007-01-11 2008-09-16 Basf Ag 2-substituted pyrimidines I in therapy
KR100936278B1 (ko) * 2007-12-14 2010-01-13 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는 피리미딘 유도체또는 이의 약학적으로 허용가능한 염을 유효성분으로함유하는 암 예방 및 치료용 조성물
US8697694B2 (en) * 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
CN111065635B (zh) * 2018-01-04 2022-07-22 无锡安万生物科技有限公司 作为mth1抑制剂的新型嘧啶衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006235A (en) * 1973-03-23 1977-02-01 Burroughs Wellcome Co. Treating CNS lymphoma
GB8314643D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Pyrimidine derivatives
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9700664D0 (en) * 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
WO2002074753A2 (de) * 2001-03-15 2002-09-26 Basf Aktiengesellschaft 5-phenylpyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekaempfung von schadpilzen
AP2003002924A0 (en) * 2001-06-12 2003-12-31 Neurogen Corp 2,5-diarylpyrazines, 2,5 - diarylpyridines and 2,5 - diarylpyrimidines as CRF1 receptor modulators
CN1312134C (zh) * 2001-11-19 2007-04-25 巴斯福股份公司 5－苯基嘧啶化合物、包含它们的组合物、其制备方法及其用途
US7320975B2 (en) * 2002-02-21 2008-01-22 Basf Aktiengesellschaft 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi
JP4860151B2 (ja) * 2002-07-22 2012-01-25 オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド 新規な生物活性分子
US7371758B2 (en) * 2003-03-13 2008-05-13 National Science & Technology Development Agency Antimalarial pyrimidine derivatives and methods of making and using them
MXPA05011549A (es) * 2003-05-20 2005-12-15 Basf Ag Pirimidinas 2 - sustituidas.
WO2005019187A1 (de) * 2003-07-24 2005-03-03 Basf Aktiengesellschaft 2-substituierte pyrimidine
JP2007506746A (ja) * 2003-09-24 2007-03-22 ワイス・ホールディングズ・コーポレイション 抗癌剤としての５−アリールピリミジン類
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
DE102004003493A1 (de) * 2004-01-23 2005-08-11 Bayer Cropscience Ag 5-Phenylpyrimidine
US20080132522A1 (en) * 2004-07-14 2008-06-05 Basf Aktiengesellschaft 2-Substituted Pyrimidines, Method for Their Production and Their Use for Controlling Pathogenic Fungi

Also Published As

Publication number Publication date
EA200701582A1 (ru) 2008-02-28
UA87895C2 (en) 2009-08-25
BRPI0607108A2 (pt) 2010-03-09
AU2006208621B2 (en) 2011-08-11
JP2008528535A (ja) 2008-07-31
MX2007008397A (es) 2007-09-07
AR054220A1 (es) 2007-06-13
WO2006079556A2 (en) 2006-08-03
EP1845991A2 (en) 2007-10-24
WO2006079556A3 (en) 2006-09-21
CA2595958A1 (en) 2006-08-03
US20080146593A1 (en) 2008-06-19
EA014098B1 (ru) 2010-08-30
AU2006208621A1 (en) 2006-08-03
TW200637556A (en) 2006-11-01
ZA200707315B (en) 2008-11-26
CN101111250A (zh) 2008-01-23
NZ556448A (en) 2010-12-24
IL184375A0 (en) 2007-10-31
PE20061042A1 (es) 2006-11-20
KR20070104893A (ko) 2007-10-29

Similar Documents

Publication Publication Date Title
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CO6470876A2 (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak.
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PA8632701A1 (es) Compuestos terapeuticos
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
CR9929A (es) Nuevos compuestos
MX348290B (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
CR11738A (es) Compuestos de pirimidinona pirrolo 3-metil-2-imino fenil sustituidos como inhibidores bace-1, composiciones y su uso
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
CO6612228A2 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
CU24087B1 (es) Compuestos de carbazol
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
CR11429A (es) Derivados bis-(sulfonilamino) en terapia 066
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
TW200509892A (en) Novel aminobenzophenone compounds
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
ECSP109964A (es) Pirimidinas bicíclicas fusionadas
ATE522534T1 (de) Pyrrolopyrazin-kinasehemmer
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
UY35393A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a